Cathie Wood Alnylam Pharmaceuticals, Inc. Transaction History

Ark Investment Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 07, 2018	SELL	$87.52 - $122.67 $1.69 Million - $2.38 Million	-19,362 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$88.31 - $107.8 $728,557 - $889,350	8,250 Added 74.24%	19,362 $1.91 Million
Q1 2018 May 14, 2018	BUY	$115.92 - $148.54 $1.04 Million - $1.34 Million	9,014 Added 429.65%	11,112 $1.32 Million
Q4 2017 Feb 12, 2018	SELL	$114.49 - $139.98 $798,682 - $976,500	-6,976 Reduced 76.88%	2,098 $267,000
Q3 2017 Nov 09, 2017	BUY	$72.53 - $118.27 $275,468 - $449,189	3,798 Added 71.99%	9,074 $1.07 Million
Q2 2017 Aug 11, 2017	SELL	N/A	-948 Reduced 15.23%	5,276 $421,000
Q1 2017 May 15, 2017	SELL	N/A	-117,506 Reduced 94.97%	6,224 $319,000
Q4 2016 Feb 13, 2017	BUY	N/A	123,730	123,730 $4.63 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Ark Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Ark Investment Management LLC and Cathie Wood with notifications on news.